Download PDF
Exp Clin Endocrinol Diabetes 2012; 120(02): 121-123
DOI: 10.1055/s-0031-1297253
Short Communication
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Benefit of Combined Triiodothyronine (LT3) and Thyroxine (LT4) Treatment in Athyreotic Patients Unresponsive to LT4 Alone

D. Solter
1   Department of Otorhinolaryngology, Head and Neck Surgery, Sisters of Mercy University Hospital Center, Zagreb, Croatia
,
M. Solter
2   University of Zagreb, School of Medicine, Department of Endocrinology Sisters of Mercy University Hospital ­Center, Vinogradska, Zagreb, Croatia
› Author Affiliations
Further Information

Publication History

received 01 September 2011
first decision 01 September 2011

accepted 15 November 2011

Publication Date:
20 December 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Despite some reports, the usefulness of levothyroxine ( LT4) and levotriiodothyronine (LT3) combination therapy in hypothyroidism remains controversial. The objective of this paper is to study a benefit of additional LT3 in athyreotic patients who failed to normalize TSH on LT4 alone even with hyperthyroid serum T4 values.

In a survey of 200 athyreotic patients treated between 2006 and 2009, about 7% failed to normalize serum TSH levels following treatment with LT4, though serum T4 values in the hyperthyroid range were achieved. These patients (characterized by serum T4≥160 nmol/L and TSH≥5.0 mIU/L), were additionally treated with 10 μg b. i. d LT3. LT3 and LT4 combination therapy resulted in decreased serum TSH levels into the normal range (12.8 vs. 1.22 mIU/L; p<0.01) and reduced LT4 dose (153.3 vs. 117.5 μg; p<0.01) required for normalization of serum T4 values (170.6 vs. 123.3 nmol/L; p<0.01). Serum T3 values were higher (1.3 vs. 2.26 nmol/L; p<0.01) than those during monotherapy with LT4.

Our results indicate a subpopulation of athyreotic patients that could significantly benefit from combined LT4 + LT3 therapy in restoring normal TSH and thyroid hormone patterns. Further research should be undertaken to provide a genetic basis for these findings.

Key words

thyrotropin - insufficiencies - thyroid
 

  • References

  • 1 Bunevicius R, Kazanavicius G, Zalinkevicius R et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340: 424-429
    CrossrefPubMedGoogle Scholar
  • 2 Fish LH, Schwartz HL, Cavanaugh J et al. Replacement dose, metabolism and bioavailability of levothyroxine in the treatment of hypothyroidism.Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316: 764-770
    CrossrefPubMedGoogle Scholar
  • 3 Grozinsky-Glasberg S, Fraser A, Nahshoni E et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism. Meta-analysis of randomized controlled trials. J Clin Endocrinol Metabol. 2006 91. 2592-2599
    PubMedGoogle Scholar
  • 4 Jonklaas J, Davidson B, Bhagat B et al. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 2008; 299: 769-777
    CrossrefPubMedGoogle Scholar
  • 5 Nygaard B, Jensen F, Kvetny J et al. Effect of combination therapy with thyroxine (T4) and 3,5,3'-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double blind, randomized cross-over study. Eur J Endocrinol 2009; 161: 895-902
    CrossrefPubMedGoogle Scholar
  • 6 Panicker V, Saravanan P, Evans J et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009; 94: 1623-1629
    CrossrefPubMedGoogle Scholar
  • 7 Wiersinga WM. Do we need still more trials on T4 and T3 combination therapy in hypothyroidism. Eur J Endocrinol 2009; 161: 955-959
    CrossrefPubMedGoogle Scholar